This review summarizes promising new targets and immunotherapy combination strategies currently under clinical development.
Amer A. Beg, PhD
Advertisement
Articles by Amer A. Beg, PhD
Advertisement
Latest Updated Articles
- Propelling Immunotherapy Combinations Into the Clinic
December 15th 2015
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA ODAC Votes No to Camizestrant for HR+/HER2– ESR1 Advanced Breast Cancer
2
FDA Approves Vepdegestrant in ER+, HER2–, ESR1-Mutated Breast Cancer
3
FDA ODAC Votes Yes to Capivasertib for PTEN-Deficient Metastatic HSPC
4
Targeting KRAS in Pancreatic Cancer: What Is Daraxonrasib’s Mechanism of Action?
5